Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. - First Quarter 2026 Performance Summary
This English translation is provided for reference only. In case of any discrepancy, the original Chinese version shall prevail.
The Company and its entire Board of Directors warrant that this announcement contains no false records, misleading statements, or material omissions, and accept joint and several liability for the authenticity, accuracy, and completeness of its contents.
The preliminary financial data for the first quarter of 2026 disclosed in this announcement have not been audited by an independent auditing firm. Investors are advised to refer to the Company’s First Quarter 2026 Report for final figures and to be aware of potential investment risks.
I. Key Financial Data and Indicators for Q1 2026 (Approximate Figures)
Note: Figures for the beginning of the reporting period are the same as those disclosed at the end of the previous year.
The following is a written summary of the key financial data:
Income Statement and Key Ratios (Q1 2026 vs. Q1 2025)
Total operating revenue was approximately 390 million RMB, representing a year-on-year increase of approximately 25%.
Operating profit was approximately 140 million RMB, an increase of approximately 47% year-on-year.
Total profit was approximately 140 million RMB, up by approximately 48% year-on-year.
Net profit attributable to shareholders was approximately 120 million RMB, an increase of approximately 48% compared with the same period last year.
Recurring net profit attributable to shareholders was approximately 120 million RMB, up by approximately 46% year-on-year.
Basic earnings per share (EPS) was approximately 0.29 RMB, an increase of approximately 16%.
Weighted average return on equity (ROE) was approximately 5.8%, representing an increase of 1.1 percentage points year-on-year.
Balance Sheet Data (End of Q1 2026 vs. Beginning of 2026)
Total assets were approximately 2.80 billion RMB, an increase of approximately 15% compared with the beginning of the period.
Total equity attributable to shareholders was approximately 2.08 billion RMB, up by approximately 6%.
Total share capital remained unchanged at approximately 420 million shares.
Net assets per share attributable to shareholders was approximately 4.96 RMB, an increase of approximately 6%.
II. Explanation of Operating and Financial Performance
(A) Operating Performance
In the first quarter of 2026, the Company maintained normal production and operations, with business activities proceeding as usual both domestically and internationally. Revenue grew steadily, and profit increased rapidly.
Total operating revenue for the first quarter of 2026 was approximately 390 million RMB, representing a year-on-year increase of approximately 25%. Net profit attributable to shareholders was approximately 120 million RMB, up by approximately 48% year-on-year. Recurring net profit attributable to shareholders was approximately 120 million RMB, an increase of approximately 46% year-on-year.
The main reasons for the growth are as follows:
Increased product sales volume due to rising demand from both domestic and overseas customers; and
Strong demand for high-value-added products, supported by an optimized product mix.
(B) Financial Position
As of the end of the first quarter of 2026, the Company’s financial position remained solid. Total assets stood at approximately 2.80 billion RMB, representing an increase of approximately 15% from the beginning of the period. Total share capital was approximately 420 million shares.
III. Risk Warning
The financial data contained in this announcement are preliminary, unaudited estimates. Investors are reminded to refer to the audited figures in the Company’s official First Quarter 2026 Report and to exercise caution regarding investment risks.
IV. Available Documents
Comparative balance sheet and income statement signed and sealed by the Company’s principal responsible person, chief accounting officer, and accounting department head.
Note: The Company is primarily engaged in the R&D, production, and sale of prebiotic series, dietary fiber series, healthy sweetener series, and other starch sugar products.